Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED NA

Safety and Effectiveness of Juvéderm® VOLUMA XC Injectable Gel for Cheek Augmentation

NCT00978042 · View on ClinicalTrials.gov ↗

Study Summary

Multicenter, single-blind, randomized, "no-treatment" control study to demonstrate the safety and effectiveness of VOLUMA XC for deep injection for cheek augmentation to correct age-related volume deficit in the mid-face.

Interventions

  • DEVICE Juvéderm® VOLUMA XC

Study Locations (2)

California

  • — Los Angeles

British Columbia

  • — Vancouver

Trial Details

FieldValue
Enrollment Target 345 participants
Start Date 2009-08
Est. Completion 2014-04
Phase NA

Sponsor

Allergan

52 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00978042

The ClinicalTrials.gov registry entry for NCT00978042 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 345 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 52 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Mid-facial Volume Deficit Related to Aging appearing as the primary indexed condition, and to 1 intervention — of which Juvéderm® VOLUMA XC is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT00978042 reports 2 study locations spanning 2 distinct geographic areas — top geographies include California, British Columbia. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT00978042 about?

NCT00978042 is a clinical study titled "Safety and Effectiveness of Juvéderm® VOLUMA XC Injectable Gel for Cheek Augmentation". Multicenter, single-blind, randomized, "no-treatment" control study to demonstrate the safety and effectiveness of VOLUMA XC for deep injection for cheek augmentation to correct age-related volume deficit in the mid-face.

What is the current status of trial NCT00978042?

This trial is currently completed. It is a NA study. The enrollment target is 345 participants. The study started on 2009-08. Estimated completion is 2014-04.

What conditions does trial NCT00978042 study?

This clinical trial studies the following conditions: Mid-facial Volume Deficit Related to Aging. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT00978042?

The interventions under investigation include: Juvéderm® VOLUMA XC (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT00978042?

This trial is sponsored by Allergan, which has 52 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT00978042 being conducted?

This trial has 2 study locations across California, British Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial